TMDX
TransMedics Group IncNASDAQHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$2.38B
P/E Ratio
15.77
EPS
$4.37
Beta
2.06
52W High
$156.00
52W Low
$60.10
50-Day MA
$97.68
200-Day MA
$119.48
Dividend Yield
—
Profit Margin
27.00%
Forward P/E
31.75
PEG Ratio
—
About TransMedics Group Inc
TransMedics Group, Inc., a commercial-stage medical technology company, is dedicated to transforming organ transplant therapy for patients with end-stage organ failure in the United States and internationally. The company is headquartered in Andover, Massachusetts.
Fundamentals
| Revenue (TTM) | $635.89M |
| Gross Profit (TTM) | $375.74M |
| EBITDA | $125.35M |
| Operating Margin | 7.65% |
| Return on Equity | 45.20% |
| Return on Assets | 5.20% |
| Revenue/Share (TTM) | $18.62 |
| Book Value | $13.81 |
| Price-to-Book | 4.82 |
| Price-to-Sales (TTM) | 3.75 |
| EV/Revenue | 4.378 |
| EV/EBITDA | 19.92 |
| Quarterly Earnings Growth (YoY) | -71.50% |
| Quarterly Revenue Growth (YoY) | 21.20% |
| Shares Outstanding | $34.56M |
| Float | $33.45M |
| % Insiders | 3.34% |
| % Institutions | 109.85% |
Historical Volatility
HV 10-Day
59.20%
HV 20-Day
105.30%
HV 30-Day
93.04%
HV 60-Day
78.80%
HV Rank
97.2%
Volatility is currently contracting
Analyst Ratings
Consensus ($117.89 target)
2
Strong Buy7
Buy2
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026